revenu million
valu usd unless otherwis note
surpris upsid idenix damag revers
view somewhat unanticip turn event success
invalid idenix patent own district court
prior juri trial result damag would like
also includ futur on-going royalti remov probability-adjust
damag charg futur royalti would result upsid
prior price target thu rais price target
recal on-going litig idenix acquir
idenix alleg patent infring sofosbuvir
hcv product two distinct mrk-relat patent lawsuit
one case tri northern district california result mrk/ion
patent render unenforc
second case district delawar relat idenix patent
juri previous award uphold patent
valid though judg note decis close
friday even judg revers juri origin find
determin idenix patent invalid lack enabl
judg grant post-trial motion argu juri mistakenli
upheld idenix patent valid light prior written descript case
decis surpris us court twice previous deni
motion type motion rare grant nonetheless
origin view succeed lack written description/
enabl like outcom believ odd success
appeal still high thu believ outcom like
maintain appeal
remov probability-adjust damag charg futur
royalti model upsid prior price target
model damag charg includ
damag charg royalti juri decis addit
royalti infring hcv product interest
probability-adjust also includ on-going prob-adjust
royalti hcv sale beyond expir patent
remov damag charg on-going royalti model yield
upsid dcf valuat addit hcv market
model updat new dcf-base price target increas
item note
take cogs-rel charg idenix verdict unlik
prior mrk/ion verdict though ultim revers
addit two case on-going lawsuit
univers minnesota alleg similar infring uom patent
sofosbuvir-contain product also file ipr
patent case on-going
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case assum reason sustain hiv
convert mani patient bictegravir/f/taf
meaning price declin hcv price share
stabil worsen volum beyond
po filgotinib po nash po axi-
cel price target deriv dcf analysi
discount rate termin growth rate
better expect hcv share retent long-term hcv
price power despit gener entrant success filgotinib
nash product higher revenu car-t product
would lead upsid estim scenario
potenti dcf base valuat would
competit impact hiv hcv franchis failur
filgotinib nash product axi-cel would lead downsid
estim scenario potenti dcf valuat
would
believ bictegravir posit phase data strong
profil along favor demograph price
dynam underpin good hiv franchis sustain
nearer-term competit
overblown expect maintain strong foundat
valuat though expect hcv declin
disrupt entrant emerg share price
stabil provid predict sustain
patient volum still contribut meaning
cash flow next decad nash
asset filgotinib car-t see sever potenti
blockbust pipelin believ kite deal
help remov overhang reaffirm willing
add potenti transform growth driver
overal expect improv sentiment help drive share
appreci low believ
appropri dcf fair valu
power demograph hiv predict hcv share
price sustain volum enabl
meaning cash flow blockbust potenti pipelin
program filgotinib nash kite acquisit add long-
term revenu potenti addit dimens compani
risk patent expiri competit may impact
lt hiv revenu new hcv competitor like compress
pricing/shar near-term unknown remain nash
competit
potenti catalyst data ph iii triumeq switch
studi interim analysi ph ii entospletinib
studi cgvhd complet ph ii nivolumab
data interim analysi ph ii/iii filgotinib uc
studi complet enrol stellar trial
selonsertib nash data finch filgotinib studi
ra axi-cel follow-up data
disclaim report intend legal advic guarante accur
inform purpos establish attorney-cli relationship
price target deriv via dcf analysi discount rate termin
growth rate post-taf gener valuat support outperform rate
risk rate price target
risk includ gener hiv entrant competit hcv efficaci safeti risk pipelin
product filgotinib selonsertib axi-cel
gilead leader develop market anti-infect drug approv
product treatment hiv/aid hepat hepat liver pulmonolog
diseas gilead develop pipelin antivir liver diseas immunolog oncolog
gilead extens world-wide sale market infrastructur
producteventtimelinedescovycomplet ph prep phase triumeq switch studi eu analysi ph studi ph ii studi psoriat enrol ph finch studi enrol ph finch studi finch studi ph ii studi ankylos enrol divers studi enrol stellar ph studi ph ii studi selonsertib selonsertib ph ii studi nivolumab gastric endpoint analysi ph ii nash easl ph ii pbc analysi ph ii studi ph ii studi cutan lupu ph ii studi sjogren endpoint ph ii combo studi r/r nuc complet ph ii studi ebola ph ii studi lung transplant ph approv eu aggress pivot ph ii zuma studi r/r indol follow-up data pivot ph ii trial adult ph trial pivot ph ii studi pediatr pivot ph ii r/r mcl trial ph ia studi anti-bcma car-t pivot studi base ph ph ia studi mage solid file tcr target solid nunuc initi ph ii capsid inhibitor initi ph anti-bcma axi-cel fxr exhibit pipelin
rheumatoid arhritisphas iiicrohn diseasephas iiiulcer colitisphas iiivari inflammatori diseasesphas iinashphas iiialcohol hepatitisphas iigastr cancerphas iiisolid tumorsphas r/r dlbcl pmbcl tfl eu dlbcl iiiindol nhl iidlbcl mab combo ir/r mcl iiadult pediatr cll inashphas iipbcphas iipscphas nashphas iicgvhdphas iihematolog malignanciesphas iiamlphas iisjogren syndromephas iicutan lupu erythematosusphas iitirabrutinib btk b-cell malignanciesphas nuc ebolaphas iipresatovir fusion inhibitor respiratori syncyti viru rsv phase bet solid tumorsphas curephas bnab hivphas capsid inhibitor hivent phase nunuc hivent phase anti-bcma mmphase imag tumorphas tumorphas imag tumorphas head neck cancerphas gen hematolog malignanciesphas gen hematolog head neck cancerpreclinicalkrassolid tumorpreclinicalhbv epigenet modulatorhbvpreclinicalneoantigenssolid fxr entospletinib selonsertib exhibit incom statement
million except per share antivir hcv harvoni- unit states- europe- international- epclusa- unit states- europe- international- unit international- vosevi- unit states- europe- international- total hiv genvoya e/c/f/taf unit states- europe- international- unit unit unit international- unit unit descovi f/taf unit states- europe- international- odefsey r/f/taf unit states- europe- international- bictarvi unit europe- international- unit zydelig- product includ cayston filgotinib prob-adjust prob-adjust selonsertib combo prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand biotechnolog
